Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

477 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Cases of Fournier's Gangrene in Kinki University].
Toyoda S, Minami T, Hashimoto M, Saito M, Shimizu N, Yamamoto Y, Hayashi T, Tsuji H, Nozawa M, Yoshimura K, Ishii T, Uemura H. Toyoda S, et al. Hinyokika Kiyo. 2015 Jun;61(6):223-6. Hinyokika Kiyo. 2015. PMID: 26153050 Free article. Japanese.
[Gas-Producing Splenic Abscess after Spleen Metastasis of Left Renal Cell Carcinoma Spleen Metastasis Successfully Treated with Sunitinib].
Kunishige R, Ozeki T, Hamaguchi M, Toyoda S, Hashimoto M, Kikuchi T, Nishimoto M, Shimizu N, Mori Y, Minami T, Nozawa M, Nose K, Yoshimura K, Uemura H. Kunishige R, et al. Among authors: toyoda s. Hinyokika Kiyo. 2021 Feb;67(2):63-66. doi: 10.14989/ActaUrolJap_67_2_63. Hinyokika Kiyo. 2021. PMID: 33657773 Free article. Japanese.
Inflammatory myofibroblastic tumor of the prostate.
Fukiage K, Fujita K, Toyoda S, Nishimoto M, Kikuchi T, Chikugo T, Yoshimura K, Esa A, Ito A, Uemura H. Fukiage K, et al. Among authors: toyoda s. IJU Case Rep. 2024 Jan 18;7(2):141-143. doi: 10.1002/iju5.12687. eCollection 2024 Mar. IJU Case Rep. 2024. PMID: 38440704 Free PMC article.
Gleason Pattern 5 May Be a Prognostic Factor in Radium-223 Treatment.
Nishimoto M, Fujita K, Ri A, Fujimoto S, Oguma Y, Toyoda S, Hashimoto M, Kikuchi T, Adomi S, Saito Y, Mori Y, Minami T, Nozawa M, Yoshimura K, Hosono M, Uemura H. Nishimoto M, et al. Among authors: toyoda s. Cancer Diagn Progn. 2024 Jul 3;4(4):441-446. doi: 10.21873/cdp.10345. eCollection 2024 Jul-Aug. Cancer Diagn Progn. 2024. PMID: 38962543 Free PMC article.
Comparative analysis of gut microbiota in hormone-sensitive and castration-resistant prostate cancer in Japanese men.
Fujimoto S, Hatano K, Banno E, Motooka D, De Velasco MA, Kura Y, Toyoda S, Hashimoto M, Adomi S, Minami T, Yoshimura K, Oka T, Hata J, Matsushita M, Takao T, Takada S, Tsujimura A, Kojima Y, Obara W, Nakamura S, Uemura H, Nonomura N, Fujita K. Fujimoto S, et al. Among authors: toyoda s. Cancer Sci. 2024 Dec 3. doi: 10.1111/cas.16408. Online ahead of print. Cancer Sci. 2024. PMID: 39628067 Free article.
First-line therapy for metastatic renal cell carcinoma: A propensity score-matched comparison of efficacy and safety.
Yanagisawa T, Mori K, Kawada T, Katayama S, Uchimoto T, Tsujino T, Nishimura K, Adachi T, Toyoda S, Nukaya T, Fukuokaya W, Urabe F, Murakami M, Yamanoi T, Bekku K, Komura K, Takahara K, Hashimoto T, Fujita K, Azuma H, Ohno Y, Shiroki R, Uemura H, Araki M, Kimura T; JK-FOOT study group. Yanagisawa T, et al. Among authors: toyoda s. Urol Oncol. 2024 Nov;42(11):374.e21-374.e29. doi: 10.1016/j.urolonc.2024.06.013. Epub 2024 Jul 31. Urol Oncol. 2024. PMID: 39085019
The efficacy of second-line tyrosine kinase inhibitor for patients with metastatic non-clear cell renal cell carcinoma following first-line immune-oncology combination therapy.
Fujita K, Matsushita Y, Toyoda S, Kojima T, Yamashita S, Taniguchi H, Monji K, Ishiyama R, Tatarano S, Masui K, Nakamura E, Kaneko T, Kitano G, Motoshima T, Shiraishi, Kira S, Murashima T, Hara H, Matsumura, Nishiyama N, Miyake H, Kitamura H, Uemura H. Fujita K, et al. Among authors: toyoda s. World J Urol. 2024 Sep 26;42(1):536. doi: 10.1007/s00345-024-05252-2. World J Urol. 2024. PMID: 39325218
Clinical outcomes and prognostic factors in metastatic nonclear cell renal cell carcinoma treated with immuno-oncology combination therapy.
Toyoda S, Fukuokaya W, Mori K, Kawada T, Katayama S, Nishimura S, Maenosono R, Tsujino T, Adachi T, Hirasawa Y, Saruta M, Komura K, Nukaya T, Yanagisawa T, Takahara K, Hashimoto T, Azuma H, Ohno Y, Shiroki R, Araki M, Kimura T, Fujita K; JK-FOOT study group. Toyoda S, et al. Jpn J Clin Oncol. 2024 Dec 7;54(12):1336-1342. doi: 10.1093/jjco/hyae108. Jpn J Clin Oncol. 2024. PMID: 39178171
477 results